Psychotropic Agents

Part I: Antipsychotics and Antidepressants

  • F. Hoffmeister
  • G. Stille

Part of the Handbook of Experimental Pharmacology book series (HEP, volume 55 / 1)

Table of contents

  1. Front Matter
    Pages I-XXIV
  2. Antipsychotics Chemistry (Structure and Effectiveness)

    1. Front Matter
      Pages 1-1
    2. J. Schmutz, C. W. Picard
      Pages 3-26
    3. P. A. J. Janssen, W. F. M. van Bever
      Pages 27-41
    4. H. J. Bein
      Pages 43-58
    5. A. Randrup, B. Kjellberg, E. Schiørring, J. Schell-Krüger, R. Fog, I. Munkvad
      Pages 97-110
    6. G. Bartholini, K. G. Lloyd
      Pages 193-212
    7. M. Ackenheil
      Pages 213-223
    8. F. Leuschner, W. Neumann, R. Hempel
      Pages 225-265
    9. B. Müller-Oerlinghausen
      Pages 267-285
    10. U. Breyer-Pfaff
      Pages 287-304
    11. F. G. Sulman, Y. Givant
      Pages 337-348
  3. Antidepressants Chemistry (Structure and Effectiveness)

    1. Front Matter
      Pages 349-349
    2. F. J. Zeelen
      Pages 351-368
    3. N. S. Kline, T. B. Cooper
      Pages 369-397

About this book

Introduction

The volumes on "psychotropic substances" in the Handbook of Experimental Phar­ macology series clearly show that the classical concept of this discipline has become too narrow in recent years. For instance, what substances are psychotropic is determined not by the criteria of the animal trial, i.e. by experimental pharmacology, but by their action on the psy­ che, which in the final analysis is only accessible to us in man. Psychotropic substances force experimental pharmacology (and thus also this Handbook) outside its tradition­ allimits, which have essentially depended on animal studies. The antipsychotics and antidepressants were not discovered in animal ex­ periments, but by chance (or more precisely, by clinical empiricism). Experienced psy­ chiatrists trained in the observation of patients recognised the efficacy of drugs, the beneficial effect of which nobody had dreamed of before: DELAY and DENICKER in the case of chlorpormazine, KLINE in the case of the monoamine oxidase inhibitors and KUHN in the case of imipramine. It was only after these discoveries that the pharma­ cologists developed experimental models of the psychoses in animal experiments. However, even today we still do not know with certainty which of the effects shown in animals is relevant for the clinical effect despite the vast abundance of individual investigations. For many years, this uncertainty led to the testing of antipsychotics (e.g. of the neuroleptic type) in models which actually produced the undesired effects.

Keywords

Acetylcholin Biotransformation Butyrophenone Diphenylbutylpiperidine Insulin Phenothiazine Rauwolfia Serotonin Thioxanthene analgesics chemistry pharmacokinetics pharmacology psychosis toxicology

Editors and affiliations

  • F. Hoffmeister
    • 1
  • G. Stille
    • 2
  1. 1.Institut für PharmakologieBayer AGWuppertal 1Germany
  2. 2.Institut für Arzneimittel des BundesgesundheitsamtesBerlin 30Germany

Bibliographic information

  • DOI https://doi.org/10.1007/978-3-642-67538-6
  • Copyright Information Springer-Verlag Berlin Heidelberg 1980
  • Publisher Name Springer, Berlin, Heidelberg
  • eBook Packages Springer Book Archive
  • Print ISBN 978-3-642-67540-9
  • Online ISBN 978-3-642-67538-6
  • Series Print ISSN 0171-2004
  • About this book
Industry Sectors
Chemical Manufacturing
Biotechnology
Consumer Packaged Goods
Pharma